Previous 10 | Next 10 |
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month Study Rapid Improvement in Clinical Outcome Measures Maintained in Patients with High Baseline Complement A...
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today annou...
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today annou...
Annexon Biosciences press release (NASDAQ:ANNX): Q1 GAAP EPS of -$0.92 beats by $0.08. Cash and cash equivalents and short-term investments were $206.7 million as of March 31, 2022. Annexon continues to expect that its current cash position is sufficient to fund its operating plans into 2024....
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023 BRISBANE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasda...
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announ...
Understanding Penny Stocks And 3 Hot Ones to Watch Now Trading penny stocks can have a lot of intricacies that inexperienced investors don’t understand. However, if you take the time to learn about this type of trading, it can be a very lucrative investment. With penny stocks ...
Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse Biosciences (PLSE) +18%. Annexon (ANNX) +18%. Olema Pharma...
Checkmate Pharmaceuticals (CMPI) +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal. Axsome Therapeutics (AXSM) +27%. Super Micro Computer (SMCI) +16% on raised Q3 guidance. 4D pharma (LBPS) +13%. American Campus Communities (ACC) +13% Blac...
Annexon (NASDAQ:ANNX) announced the completion of enrollment in the Phase 2 ARCHER trial evaluating its candidate, ANX007, to treat patients with geographic atrophy (GA). The company plans to report topline data from the trial in H1 2023, following 12 months of treatment, with full data ...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...